德国ITM异体技术公司与德比奥法姆合作,获得全球专属许可,开发针对癌症治疗的放射性药物. ITM Isotope Technologies Munich SE partners with Debiopharm for exclusive global license to develop targeted radiopharmaceuticals for cancer treatment.

德国ITM Isotope Technologies Munich SE已获得Debiopharm的全球专属许可,用于开发针对CA IX的基于的放射性药物. ITM Isotope Technologies Munich SE has secured an exclusive global license from Debiopharm for developing peptide-based radiopharmaceuticals targeting CA IX in solid tumors. 这一伙伴关系旨在推进癌症创新治疗,增强肿瘤学定向治疗的潜力。 This partnership aims to advance innovative treatments for cancer, enhancing the potential for targeted therapy in oncology.